---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-058085"
form_type: "8-K"
ticker: "ESLA"
cik: "0001844417"
company_name: "Estrella Immunopharma, Inc."
filed_at: "2024-07-02T23:59:59+00:00"
generated_at: "2026-05-31T23:49:55.127389+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Estrella Immunopharma merges wholly-owned sub Estrella Biopharma into parent

## Summary
- Merger effective June 30, 2024; Estrella Biopharma ceased to exist, Estrella Immunopharma survives.
- No changes to management, board, ownership, charter, or bylaws as a result of the merger.
- Merger approved by unanimous written consent of board; intended to simplify corporate structure and streamline financial reporting.

## SEC filing metadata
- accession: 0001213900-24-058085
- form_type: 8-K
- ticker: ESLA
- cik: 0001844417
- company_name: Estrella Immunopharma, Inc.
- filed_at: 2024-07-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1844417/000121390024058085/0001213900-24-058085-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1844417/000121390024058085/ea0208757-8k_estrella.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-058085
- JSON: https://secwatch.observer/filing/0001213900-24-058085.json
- Plain text: https://secwatch.observer/filing/0001213900-24-058085.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.